GMF-beta Antibody - BSA Free

Immunohistochemistry-Paraffin: GMF-beta Antibody - BSA Free [NBP1-89755]

Staining of human skeletal muscle shows no cytoplasmic positivity in myocytes as expected.

Immunohistochemistry-Paraffin: GMF-beta Antibody - BSA Free [NBP1-89755]

Staining of human cerebral cortex shows moderate cytoplasmic positivity in neurons.

Immunohistochemistry-Paraffin: GMF-beta Antibody - BSA Free [NBP1-89755]

Staining of human liver shows no cytoplasmic positivity in hepatocytes as expected.

Immunohistochemistry-Paraffin: GMF-beta Antibody - BSA Free [NBP1-89755]

Staining of human cerebellum shows moderate cytoplasmic positivity in Purkinje cells.

Western Blot: GMF-beta Antibody - BSA Free [NBP1-89755]

Analysis in human cell line A-431.

Western Blot: GMF-beta Antibody - BSA Free [NBP1-89755]

Analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.

Immunocytochemistry/ Immunofluorescence: GMF-beta Antibody [NBP1-89755]

GMF-beta-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-89755-img0020.jpg

Immunohistochemistry: GMF-beta Antibody [NBP1-89755]

GMF-beta-Antibody-Immunohistochemistry-NBP1-89755-img0019.jpg

Immunohistochemistry: GMF-beta Antibody [NBP1-89755] -

Immunohistochemistry: GMF-beta Antibody [NBP1-89755] - GMF-beta knockdown suppresses tumor growth & the formation of human-CD31 positive microvessels (hCD31-MVs) in orthotopic U87 xenograft modelsA. The cross-sectional appearance of xenografted gliomas from U87-mock group B. The cross-sectional appearance of xenografted gliomas from U87-shGMF-beta group. Gross tumor boundaries were delineated by white dotlines. C. A hCD31-microvessel & several hCD31-negative vessels in U87-mock tumor. D. No hCD31-MVs, only hCD31-negative vessels in U87-shGMF-beta tumor. Red solid arrows indicate hGMF-beta staining in tumor cells, black solid arrows show hCD31 staining on microvasular endothelia, & open arrows denote vessels negative for hCD31. Scale bar: 100 μm in upper pannels; 50 μm in lower pannels. E. Quantitative comparisons of gross tumor volume between U87-mock & U87-shGMF-beta group. F. Quantitative comparisons of hCD31-microvessel densities (MVDs) between U87-mock & U87-shGMF-beta group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26515590), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GMF-beta Antibody [NBP1-89755]

GMF-beta-Antibody-Western-Blot-NBP1-89755-img0022.jpg

Western Blot: GMF-beta Antibody [NBP1-89755]

GMF-beta-Antibody-Knockdown-Validated-NBP1-89755-img0021.jpg

Western Blot: GMF-beta Antibody [NBP1-89755] -

Western Blot: GMF-beta Antibody [NBP1-89755] - Tubulogenesis of human U87 glioblastoma cells is inhibited by GMF-beta knockdownA. Protein levels of GMF-beta in human glial cell line (HEB) & human glioma cell lines of the different grades (CHG5, SHG44, U87). B. Assessment of GMF-beta knockdown in U87 cells by western blotting. C. Tube formation by U87 mock cells (left panel); impaired tube formation by U87-shGMF-beta cells (right panel). Inspection under a phase contrast fluorescent microscope (× 100). D. Quantified tubulogenesis of U87 mock cells & U87-shGMF-beta cells by pattern recognition system (left panel) & branch point counting system (right panel).*** indicates significant difference with P < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26515590), licensed under a CC-BY license. Not internally tested by Novus Biologicals.